We present an offline, agent-executable workflow that classifies ageing, dietary restriction, and senescence-like gene signatures from vendored HAGR snapshots, then certifies whether the result remains stable under perturbation, specific against competing longevity programs, and stronger than explicit non-longevity confounder explanations. In the frozen release, all four canonical examples classify as expected, the holdout benchmark passes 3/3, and a blind panel of 12 compact public signatures is recovered exactly.
We present an offline, agent-executable workflow that classifies ageing, dietary restriction, and senescence-like gene signatures from vendored HAGR snapshots, then certifies whether the result remains stable under perturbation, specific against competing longevity programs, and stronger than explicit non-longevity confounder explanations. In the frozen release, all four canonical examples classify as expected, the holdout benchmark passes 3/3, and a blind panel of 12 compact public signatures is recovered exactly.
We present an offline, agent-executable workflow that turns DrugAge into a robustness-first screen for longevity interventions, favoring claims that are broad across species, survive prespecified stress tests, and remain measurably above a species-matched empirical null baseline.
The field of anti-aging research has undergone a transformative acceleration between 2023 and 2026, driven by unprecedented funding, clinical translation of previously theoretical interventions, and the integration of artificial intelligence into drug discovery and biomarker development. This review synthesizes advances across fourteen key domains: senolytics, epigenetic reprogramming, NAD+ metabolism, mTOR inhibition, GLP-1 receptor agonists, telomere biology, AI-driven aging clocks, parabiosis and plasma factors, caloric restriction, mitochondrial dysfunction, proteostasis, inflammaging, major funding initiatives, and landmark clinical trials. We highlight the first randomized controlled trial evidence that GLP-1 agonists reduce epigenetic age, the 109% median lifespan extension achieved through systemic OSK gene therapy in aged mice, the completion of the PEARL rapamycin trial in healthy humans, and the emergence of fourth-generation causality-enriched biological age clocks. Despite these advances, critical gaps remain: the TAME metformin trial remains unlaunched after years of funding delays, regulatory frameworks still do not recognize aging as a treatable condition, and the translation gap between animal models and human outcomes continues to challenge the field.
